Close
CDMO Safety Testing 2026
Novotech

Clinical Trials

Kiadis Pharma receives regulatory approval for next trials for ATIR101 and ATIR201

Kiadis Pharma N.V. , a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders announces that it has obtained regulatory approval from the national authority in Belgium. The FAGG,...

Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

Selvita , a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML)....

LEO Pharma announces positive results from phase 2b clinical study for tralokinumab in atopic dermatitis

LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema.ย  Tralokinumab is...

Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases

Inovio Pharmaceuticals, Inc. announced that Dr. David B. Weiner, Inovioโ€™s co-founder, presented positive clinical data on Inovioโ€™s DNA-based vaccines against MERS (GLS-5300) and Zika (GLS-5700) at the Coalition for Epidemic Preparedness Innovation (CEPI)โ€™s 1st Scientific Meeting on โ€œVaccines Against...

Delmar Pharmaceuticals announces dosing of first patient in Phase two clinical trial of VAL-083

DelMar Pharmaceuticals, Inc , a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Announced that patient dosing has commenced in a Phase 2 clinical study of its investigational drug VAL-083 (dianhydrogalactitol) for...

Aslan pharmaceuticals announces first patient enrolled in phase 1 study of Varlitinib in japan

ASLAN Pharmaceuticals , a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types announced that they are initiating enrolment of the first patient in the phase 1 clinical trial for varlitinib (ASLAN001)...

Envisia therapeutics releases interim Env515 phase 2 data resultsย 

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial in patients with glaucoma. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป